Orchid Pharma Limited has informed the Exchange about Credit Rating- Revision
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CARE Ratings has downgraded Orchid Pharma's long-term credit rating from CARE A- to CARE BBB+ with a Stable outlook. The downgrade reflects recent operational and financial performance for FY25 and 9MFY26, the pending NCLT order on a scheme of amalgamation, and the completion of an asset acquisition related to an own molecule. The short-term rating of CARE A2 has been reaffirmed. The previous Rating Watch with Developing Implications has been removed. Total rated facilities stand at Rs. 366.50 crore across long-term and short-term bank facilities.
The downgrade signals reduced creditworthiness and may increase borrowing costs. While BBB+ remains investment grade, the downgrade suggests higher financial risk and could impact investor sentiment negatively.